





Table 7. Ad Model 6	ljusted estimates of group-level incidence	e rates of nephrolithiasis in South Carolin	a by age and race from 1997 to 2012
Model 6: Age Group (yr)	5-yr Change in Kidney Stone Incidence among Whites (95% Confidence Interval)	5-yr Change in Kidney Stone Incidence among Blacks (95% Confidence Interval)	5-yr Change in Kidney Stone Incidence among Other Races (95% Confidence Interval)
<10	1.11 (0.99 to 1.24)	1.23 (0.89 to 1.69)	0.53 (0.15 to 1.93)
10-14	1.21 (1.13 to 1.29)	1.15 (0.89 to 1.50)	0.94 (0.51 to 1.72)
15-19	1.25 (1.20 to 1.28)	1.37 (1.23 to 1.52)	1.70 (1.34 to 2.16)
20-24	1.13 (1.10 to 1.15)	1.30 (1.22 to 1.38)	1.15 (1.02 to 1.31)
25-34	1.05 (1.04 to 1.07)	1.21 (1.16 to 1.26)	1.13 (1.04 to 1.21)
35-44	1.06 (1.05 to 1.07)	1.20 (1.16 to 1.25)	1.26 (1.18 to 1.36)
45-64	0.95 (0.94 to 0.96)	1.05 (1.02 to 1.07)	1.63 (1.52 to 1.73)
≥65	1.06 (1.04 to 1.07)	1.17 (0.83 to 1.65)	2.44 (1.68 to 3.53)













COMMON CLINICAL ASSOCIATIONS• BONE FRACTURE, OSTEOPOROSIS• HYPERTENSION• CORONARY ARTERY DISEASE• CHRONIC KIDNEY DISEASE/ESRDYayor EN, et al, K1 2005Currant PA, et al, K1 2005Stramer HM, et al K1 2005Kamer HM, et al K1 2005Kamer HM, et al K1 2005Currant PA, et al K1 2005





ASSOCIATION WITH VASCULAR CALCIFICATION


- YOUNG KIDNEY STONE FORMERS WITH HIGHER PREVALENCE OF SUBCLINICAL ATHEROSCLEROSIS BASED ON INCREASED CAROTID INTIMA-MEDIA WALL THICKNESS
- HIGHER CAROTID-RADIAL AND CAROTID-FEMORAL PULSEWAVE VELOCITIES IN STONE FORMERS AND CORRELATED TO LOWER BMD T-SCORES
- KSF HAVE HIGHER AAC SCORES RELATIVE TO AGE AND SEX MATCHED CONTROLS

REINER AP, ET AL: . J UROL 2011, FABRIS A, ET AL J NEPHROL 2014, SHAVIT L, ET AL. CJASN 2015









	Disaster	of urolithiasis.	In the section of the second	Dharantara
	Disorder	Gene	Inheritance	
	Autosomal dominant idiopathic hypercalciuria	ADCYTU and VDR	AD	 Normocalcemia and normal PTH
	Autosomal dominant	CASR and GNA11	AD	Hypocalcemia, hyperphosphatemia, hyp
	hypocalcemia with			magnesemia, and low to normal range PTH
0	hypercalciuria Bartter syndrome			
	Type I	NKCC2 (SLC12A1)	AR	• Antenatal or postnatal nephrocalcinosis, h
	Trace II	DOWN WOULD	AR	pokalemia, and metabolic alkalosis • Antenatal/postnatal nephrocalcinosi
0	Type II	• ROMK (KCNJ1)	AK	 Antenatal/postnatal nephrocalcinosi hyperkalemia in infancy, postnatal hypoka- lemia, late-onset nephrocalcinosis, and CK
	Type III	• CLCNKB	AR	 Hypokalemic metabolic alkalosis, nep rocalcinosis, and late-onset symptoms
MONOGENIC	Type IVa	BSND	AR	 Sensorineural hearing loss and early-ons- CKD
ASSOCIATIONS WITH	Type IVb	CLCNKB and CLCNKA	AR	 Renal salt wasting and sensorineural hearing loss
	Туре V	MAGED2	XLR	 Salt wasting, polyuria, hypokalemia, nep rocalcinosis, and antenatal onset
STONES	Dent disease Type 1	CLCN5	XLR	LMW proteinuria, nephrocalcinosis, and CP
JIONES	Type T	• CLUND	ALR	 Low proteinuria, nephrocatchosis, and CP with progression to ESRD
	Type 2	• OCRL	XLR	 LMW proteinuria and nephrocalcinosis (le frequent than type 1)
	Hereditary hypophosphatemic rickets with hypercalciuria	 SLC34A1, SLC34A3, and SLC9A3R1 	AR	 Low serum phosphate, hypophosphatemi normocalcemia, and elevated 1,25(OH)₂ vitamin D
	Familial hypomagnesemia with hypercalciuria and nephrocalcinosis	CLDN16 and CLDN19	AR	 Hypomagnesemia, nephrocalcinosis, ar progression to ESRD in adolescence
	Distal renal tubular acidosis	ATP6V1B1, ATP6V0A4, and SLC4A1	AD	 Hypokalemia, metabolic acidosis, nep rocalcinosis, growth delay, early-onset sensorineural deafness, and metabolic bon disease
	Primary hyperoxaluria	AGXT, GRHPR, and HOGA1	AR	CKD with progression to ESRD and risk systemic oxalosis
	Infantile hypercalcemia	CYP24A1 and SLC34A1	AR	Hypercalcemia
	Cystinuria	 SLC3A1 and SLC7A9 HPRT1 	AR or AD XLR	 Cystine stones and nephrocalcinosis Hyperuricemia, neurologic deficits (psych
	Hereditary hyperuricosuria	• ned 1	ALR	 Hyperunicemia, neurologic deficits (psych motor delay, intellectual disability), and renal failure
	Hereditary xanthinuria	 XDH, MOCOS, MOCS1, MOCS2, and GPHN 	AR	 Myopathy, psychomotor deficit, grow delay, seizure, and hypotonia
Chul Koo, et al. Asian J Urol 2022	Adenine phosphoribosyltransferase deficiency	• APRT	AR	Crystalluria and progressive CKD
	AD, autosomal dominant; AR, aut weight; PTH, parathyroid hormone		idney disease; I	ESRD, end-stage renal disease; LMW, low molecul

MONOGENIC ASSOCIATIONS WITH STONES -EVEN MORE LIKELY IN KIDS

- 14 GENES ACCOUNTED 15% OF ALLCOMERS IN STONE CLINIC
 - 11% OF ADULTS, 29% OF KIDS
- 15/51 PATIENTS WITH FIRST STONE PRIOR TO AGE 25 IN ANOTHER CLINIC WITH PATHOGENIC SINGLE GENE MUTATION (29%)
- 24/32 PATIENTS SUSPECTED TO HAVE A HEREDITARY CAUSE OF STONE DISEASE HAD A PATHOGENIC MUTATION (75%)

Halbritter J et al, JASN 2014 Daga A et al, Kidney Int 2018 Huang L et al Mol Genet Genom 2022

Disorder	OMIM#		Age onset	Clinical features Type o stone	I
		amily 24 Subfamily A poly-peptide 1		Muscle: hypotonia Neurologic: lethargy - Lao aonormannes: nypokaienna, increaseu serum prostagianum 12, hyperprostaglandinuria, hypercalciuria, occasional hypomagnesemia, hypochloremia, increased urinary potassium and chloride, hyposthenuria	
Bartter Syndrome Type 3	607364	CLCNKB Chloride Channel Voltage-sensitive Kb	Variabl	le Eyes: multifocal yellow-white geographic, solid, choroidal lesions along the retinal vascular arcades, echogenic placoid calcified lesions at level of the scler and choroid, normal retina and retinal pigment epithelium overlaying lesions <i>Vascular</i> : low blood pressure <i>Kidneys</i> : renal salt wasting, renal potassium wasting, impaired reabsorption of chloride, polyuria, nephrolithiasis <i>Muscle</i> : generalized weakness <i>Metabolic features</i> : dehydration, hypokalemic metabolic alkalosis <i>Endocrine</i> : hyperactive renin-angiotensin system, elevated plasma renin, elevated plasma aldosterone <i>Lab findings</i> : hypokalemia, increased serum bicarbonate, increased urinary potassium and chloride, hypocalciuria or normocalciuria	Calcium a
Hypocalcemia, autosomal dominant with Bartter Syndrome & ADH	601198	CASR Calcium-sensing Receptor	~ 4 yea	ars Growth: short stature (rare) Larynx: laryngospasm (rare) Kidneys: hypercalciuria, nephrocalcinosis, nephrolithiasis, decreased renal function Skeletal: osteoarthritis, increased bone mineral density in lumbar spine Muscle: muscle cramp, carpopedal spasm, tetany	Calcium
Type 2 Schott C et al, Fr	ontiers Urg	otassium Inwardly-	спата	<i>Growin</i> , snort stature, low on the weight, failure to thrive Calcium Head: large head, prominent forehead, triangular face, large pinnae, large eyes Vascular: low-to-normal blood pressure Gastrointestinal: constipation, vomiting, diarrhea	
	Ν	lember 1		Kidneys: renal salt wasting, renal potassium wasting, renal juxtaglomerular cell	


FAMILY HISTORY AND STONES


IDIOPATHIC STONE DISEASE IS A POLYGENIC DISORDER WITH A STRONG INFLUENCE OF ENVIRONMENT ON EXPRESSION





DIET IS NOT PURELY	EN	VIRC)N/	νEI	VT/	۹L			0
		RITABILITY KE AND N	IEAL M OF	YSIS FO ACRON MZ ANI	UTRIEN D DZ T	T AND			_
A DECEMBER OF A		Intrac Correla			oner ability	L	ISREL E	stimates	
		r _{MZ}	r _{DZ}	h ²	F Test	e ²	h_a^2	c ² Fit	
	Freq. KCal	0.403 0.598 >*	0.286	0.324 0.623	2.61*	0.352		0.99	D†
	Grams Carb.	0.554 0.605 >*	0.340	0.427	1.75* 2.24*	0.425	0.575	0.92	- /
	Fat	0.401	0.250	0.303	1.88*	0.534	0.466	0.97	0†
a grant to be a second a second	Prot.	0.534 >*		0.529	2.24*	0.419	0.582	0.97	
	Alc. H ₂ O	0.494 0.540	0.265 0.371	0.457 0.339	1.37 1.62*	0.517 0.436	0.483 0.564	0.993	
		able 1 for s							
de Castro JM. Physiol & Behavior 1993	4	o (C			0		

Heritabilities of Dietary	Measures							
	<i>h</i> ² unadjusted	<i>h</i> ² unadjusted p-value	Proportion of variance of measure explained by covariates	h ² adjusted for age, gender, height, weight	h ² adjusted for age, gender, height, weight p- value			
FFQ Dietary intake	1							
Total Protein, g	0.45	<0.001	10.8%	0.37	<0.001			
Animal Protein, g	0.31	0.002	12.3%	0.24	0.013			
Calcium, mg	0.56	< 0.001	2.7%	0.50	<0.001			
Oxalate, mg	0.25	0.011	2.7%	0.22	0.021			
Fructose, g	0.26	0.007	2.6%	0.23	0.016			
Sucrose, g	0.37	< 0.001	2.2%	0.38	< 0.001			
Urine variables that reflect diet intake								
Sodium, mmol/day	0.00	0.50	16.5%	0.07	0.23			
Potassium, mmol/day	0.00	0.50	16.2%	0.005	0.47			
Volume, ml/day	0.30	0.002	1.9%	0.24	0.01			
Adjusted models included age, se	ex, height, and weig	cht.						










Stone	Risk F	actors /	Cystine So	creening:	Negativ	e (07/31/	/2023)			
DATE	SAMPLE ID	Vol 24	SS CaOx	Ca 24	0x 24	Cit 24	SS CaP	pН	SS UA	UA 24
03/27/24	\$2757446	7 2.56	4.38	226	34	603	0.60	6.091	0.48	0.714
07/29/23	S2747743	• 1.28	7.20	142	36	594	0.66	5.911	1.12	0.612
	ENCE RANGE	0.5 - 4L	6 - 10	male <250 female <200	20 - 40	male >450 female >550	0.5 - 2	5.8 - 6.2	0-1	male <0.800 female <0.750
Dieta DATE	sample id	Na 24	K 24	Mg 24	P 24	Nh4 24	CI 24	Sul 24	UUN 24	PCR
	\$27574467	217	40	109	0.782	<mark>50</mark>	214	45	10.92	
07/29/23	\$27477430	142	55	119	0.611	35	153	44	8.98	1.2
REFERE	NCE RANGE	50 - 150	20 - 100	30 - 120	0.6 - 1.2	15-60	70 - 250	20 - 80	6-14	0.8 - 1.4
Norm	alized V	/alues								
DATE	SAMPLE ID	WEIGHT	Cr 24	Cr 24/Kg	Ca 24/	Kg Ca 24	4/Cr 24			
03/27/24	\$27574467		1111				03			
07/29/23	\$27477430	55.8	809	14.5	2.5	1	.76			
REFEREN	NCE RANGE			male 11.9-24.4 female 8.7-20.3			34-196 e 51-262			


	Chemistry	AGE	MALE MEAN	MALE SD	FEMALE MEAN	FEMALE SD	0
	SS CaOx	0 - 3.9	6.5	8.2	4.4	3.9	
		4 - 6.9	6.2	4.7	4.1	3.2	
		7 - 9.9	8.8	13.1	5.5	4.3	
		10 - 12.9	7.0	6.2	5.5	4.6	
		13 - 16	5.3	4.6	3.3	3.9	
	Ca 24/Kg	1 - 16	2.4	0.7	2.4	0.7	
	0x24/1.73 m2	0 - 3.9	35.4	22.7	30.4	17.7	
		4 - 6.9	35.3	25.9	29.0	18.3	
		7 - 9.9	28.2	11.1	30.4	21.5	
		10 - 12.9	28.9	14.7	27.6	38.3	
		13 - 16	30.1	24.3	28.2	21.6	
	Cit 24/Cr 24	2 - 4.9	761	350	1012	350	
		5 - 7.9	689	208	722	262	
		8 - 10.9	663	260	735	281	
		11 - 13.9	525	240	629	270	
		14 - 16.9	360	168	537	225	
	pH	0 - 3.9	6.70	0.8	6.90	0.79	
		4 - 6.9	6.45	0.67	6.50	0.4	
		7 - 9.9	6.27	0.61	6.34	0.61	
		10 - 12.9	6.38	0.54	6.38	0.88	
		13 - 16	6.41	0.59	6.37	0.64	
	Ua24/1.73 m ²	1 - 16	0.52	0.15	0.52	0.15	
	P 24/Kg	0 - 3.9	24.4	7.5	13.8	7.0	
		4 - 6.9	17	10.5	14.8	5.9	
		7 - 9.9	16.4	7.4	14.3	7.2	0
		10 - 12.9	15.5	7.0	11.1	5.2	-
		13 - 16	13.3	8.1	13.1	6.9	
	Mg 24/Kg	0 - 3.9	2.1	1.1	1.7	1.1	
		4 - 6.9	2.1	1.3	2.0	1.3	
		7 - 9.9	2.1	1.2	2.0	1.3	
		10 - 12.9	1.7	0.9	1.2	0.9	
and the second se		13 - 16	1.3	1.5	1.2	0.6	0

0	Table 1 Dieta	ary factors and potential stone risk.
Dietary Factors	Modification	Potential Stone Risk
Fluid intake	Reduction	Increased urine saturation
Sodium intake	Increase	Increased urine calcium and reduced citrate excretion
Calcium intake	Reduction	Increased urinary oxalate excretion
Meat intake	Increase	Low urine pH, increased urine calcium and reduced citrate excretion
Fruits intake	Reduction	Low urine pH and reduced citrate excretion
Diet content in oxalate foods	Increase	Increased urinary oxalate excretion
Ferraro PM, Nutrients 2020		.00.00




urinary stone disease	risk factors among children with
Risk factor	Prevalence among paediatric stone formers (%) ^a
Low urine volume/high urine osmolality	53–63
Hypercalciuria	13–47
Hypocitraturia	9–29
Hyperoxaluria	3–20
Hyperuricosuria	2-6
Hypomagnesuria	7-9
Reproduced from [5,10–15].	





00		FIC RECOMMEN	_	0
	urinary stone diseas			
		Water into	ıke per day	
	Age (years)	Litres	Ounces	
	Infant	0.75	25	
	Preschool	1	34	
	School-age	1.5	51	
	Adolescent	2	66	0.
	Adult	2.5-4	85-135	
D. Curr Opin P	red 2020	° ()		Š











Table 3. Recomm urinary stone dised	nended sodium intake for children with ase
Age (years)	Sodium intake (mg per day)
1–3	1000
4-8	1200
9-14	1500
14+	2000
Sas D. Curr Opin Ped 2020	° O O •














	Table 1. Current re	ecommendat	tions for pro	otein requi	rements, es	stimated by	age an	d sex, for	
-			EFSA ¹		DRI ²				
		AR (g/kg bw/d)	PRI (g/kg bw/d)	PRI (g/d)	EAR (g/kg bw/d)	RDA (g/kg bw/d)	RDA (g/d)	AMDR (%E) ³	
	4–8 years	0.72	0.89	19.30	0.76	0.95	19	10–30%	
	9-13 years	0.72	0.90	34.50	0.76	0.95	34	10–30%	
	14–17 years, boys	0.71	0.88	53.25	0.73	0.85	52	10–30%	
	14-17 years, girls	0.69	0.85	46.50	0.71	0.85	46	10–30%	
	¹ From Ref. [26] Distribution Rang Estimated Averag	ge; AR, Ave	rage Requi	irement; D	RI, Dietary	Reference	Intakes	; EAR,	0



